Abstract
Sixty patients with stage IIIA and IIIB breast cancer have been treated with a combined modality approach including induction chemotherapy, surgery and adjuvant chemotherapy: 74.5% of patients achieved an objective response after 3 cycles of induction chemotherapy, and 98.3% of patients were rendered disease-free after induction chemotherapy and surgery or radiotherapy; at 4 years, actuarial survival and disease-free survival are 71.5% and 43%, respectively. These results are significantly better than our historical control, and locally advanced breast cancer must now be considered a curable disease when treated with an aggressive multimodal approach.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Breast Neoplasms / drug therapy
-
Breast Neoplasms / pathology
-
Breast Neoplasms / radiotherapy
-
Breast Neoplasms / surgery*
-
Combined Modality Therapy
-
Cyclophosphamide / administration & dosage
-
Diethylstilbestrol / administration & dosage
-
Doxorubicin / administration & dosage
-
Female
-
Fluorouracil / administration & dosage
-
Humans
-
Mastectomy, Radical*
-
Methotrexate / administration & dosage
-
Middle Aged
-
Neoplasm Staging
Substances
-
Diethylstilbestrol
-
Doxorubicin
-
Cyclophosphamide
-
Fluorouracil
-
Methotrexate